000 04173nam a22005535i 4500
001 978-981-97-1471-1
003 DE-He213
005 20251030111821.0
007 cr nn 008mamaa
008 240416s2024 si | s |||| 0|eng d
020 _a9789819714711
_9978-981-97-1471-1
024 7 _a10.1007/978-981-97-1471-1
_2doi
050 4 _aHC411-495
072 7 _aKC
_2bicssc
072 7 _a1F
_2bicssc
072 7 _aBUS035000
_2bisacsh
072 7 _aKC
_x1F
_2thema
100 1 _aAgten, Sven.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_975292
245 1 0 _aBiopharma in China
_h[electronic resource] :
_bInnovation, Trends and Dealmaking /
_cby Sven Agten, Ben Wu.
250 _a1st ed. 2024.
264 1 _aSingapore :
_bSpringer Nature Singapore :
_bImprint: Palgrave Macmillan,
_c2024.
300 _aVII, 155 p. 35 illus., 34 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aChapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril -- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class -- Chapter 5: The art of the biopharma deal: The China angle -- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.
520 _aThis book provides an insider’s overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn’t, and how as a foreign company can tap into the world’s second largest healthcare market. Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma. Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities.
650 0 _aAsia
_xEconomic conditions.
_968942
650 0 _aMedicine
_xResearch.
_962598
650 0 _aBiology
_xResearch.
_965629
650 0 _aTechnological innovations.
_959244
650 1 4 _aAsian Economics.
_968943
650 2 4 _aBiomedical Research.
_965633
650 2 4 _aEconomics of Innovation.
_970986
700 1 _aWu, Ben.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_975293
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9789819714704
776 0 8 _iPrinted edition:
_z9789819714728
776 0 8 _iPrinted edition:
_z9789819714735
856 4 0 _uhttps://doi.org/10.1007/978-981-97-1471-1
912 _aZDB-2-ECF
912 _aZDB-2-SXEF
999 _c59172
_d59172